CN101015659A - 一种用于辅助降血糖的保健食品及其制备方法 - Google Patents
一种用于辅助降血糖的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN101015659A CN101015659A CNA2007100552651A CN200710055265A CN101015659A CN 101015659 A CN101015659 A CN 101015659A CN A2007100552651 A CNA2007100552651 A CN A2007100552651A CN 200710055265 A CN200710055265 A CN 200710055265A CN 101015659 A CN101015659 A CN 101015659A
- Authority
- CN
- China
- Prior art keywords
- extract
- under
- thick paste
- cream powder
- dried cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 title description 72
- 239000008280 blood Substances 0.000 title description 72
- 235000000346 sugar Nutrition 0.000 title description 24
- 238000000034 method Methods 0.000 title description 13
- 230000008569 process Effects 0.000 title description 3
- 239000007901 soft capsule Substances 0.000 claims abstract description 46
- 239000000843 powder Substances 0.000 claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 235000013402 health food Nutrition 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 25
- 239000006071 cream Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 15
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 15
- 241000218628 Ginkgo Species 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007766 cera flava Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 239000004519 grease Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 81
- 239000008103 glucose Substances 0.000 description 81
- 230000037396 body weight Effects 0.000 description 41
- 206010012601 diabetes mellitus Diseases 0.000 description 29
- 230000000694 effects Effects 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 235000012054 meals Nutrition 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000007872 degassing Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 206010020710 Hyperphagia Diseases 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 208000022530 polyphagia Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940127017 oral antidiabetic Drugs 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PMUIBVMKQVKHBE-UHFFFAOYSA-N [S].NC(N)=O Chemical compound [S].NC(N)=O PMUIBVMKQVKHBE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
实施例号 | 人参果(kg) | 山药(kg) | 五味子(kg) | 银杏叶提取物(kg) | 玉米胚芽油(kg) | 蜂蜡(kg) |
1 | 20 | 20 | 10 | 2 | 5 | 0.05 |
2 | 25 | 28 | 18 | 3.5 | 12 | 0.3 |
3 | 36 | 30 | 24 | 4.2 | 18 | 0.6 |
4 | 42 | 35 | 28 | 5.5 | 22 | 1.3 |
5 | 50 | 50 | 50 | 20 | 30 | 2 |
剂量(g/kg体重) | 初始体重 | 中期体重 | 结束体重 | P值 | |||
动物数(只) | 体重(g) | 动物数(只) | 体重(g) | 动物数(只) | 体重(g) | ||
0.0 | 12 | 25.7±0.58 | 12 | 29.8±1.24 | 12 | 31.5±1.29 | |
1.0 | 12 | 25.8±0.86 | 12 | 29.6±0.74 | 12 | 31.1±0.73 | P>0.05 |
剂量 | 初始体重 | 中期体重 | 结束体重 | P值 | |||
(g/kg体重) | 动物数(只) | 体重(g) | 动物数(只) | 体重(g) | 动物数(只) | 体重(g) | |
0.0 | 15 | 25.7±1.37 | 15 | 27.2±1.39 | 15 | 28.6±1.44 | |
0.17 | 15 | 25.8±1.33 | 15 | 27.4±1.28 | 15 | 29.2±1.71 | P>0.05 |
0.33 | 15 | 25.9±1.38 | 15 | 27.3±1.22 | 15 | 29.4±1.69 | P>0.05 |
1.0 | 15 | 25.8±1.16 | 15 | 27.3±1.09 | 15 | 29.3±1.37 | P>0.05 |
剂量 | 动物数 | 空腹血糖值(mmol/L) | ||
(g/kg体重) | (只) | 给受试物前 | 给受试物后 | P值 |
0.0 | 12 | 6.5±0.51 | 6.2±0.74 | |
1.0 | 12 | 6.5±0.47 | 6.1±0.72 | P>0.05 |
剂量(g/kg体重) | 动物数(只) | 实验前血糖值(mmol/L) | 实验后血糖值(mmol/L) | P值 | 血糖下降百分率(%) | P值 |
0.0 | 15 | 17.9±3.25 | 20.8±5.66 | -14.9±21.3 | ||
0.17 | 15 | 17.9±3.25 | 20.4±5.93 | P>0.05 | -12.9±28.9 | P>0.05 |
0.33 | 15 | 18.0±3.23 | 17.9±5.19 | P>0.05 | 0.49±22.3 | P>0.05 |
1.0 | 15 | 18.0±3.20 | 19.2±5.31 | P>0.05 | -5.69±19.8 | P>0.05 |
剂量 | 动物数 | 给葡萄糖后血糖值(mmol/L) | ||||||
(g/kg体重) | (只) | 零时值 | 0.5h值 | P值 | 2h值 | P值 | 血糖曲线下面积 | P值 |
0.0 | 15 | 19.9±5.37 | 28.6±4.02 | 23.0±4.30 | 50.8±8.43 | |||
0.17 | 15 | 19.7±5.74 | 27.5±3.74 | P>0.05 | 22.2±4.94 | P>0.05 | 49.1±8.72 | P>0.05 |
0.33 | 15 | 17.4±5.10 | 24.2±3.82 | P<0.05 | 18.9±4.28 | P<0.05 | 42.7±8.14 | P<0.05 |
1.0 | 15 | 18.6±5.15 | 25.5±5.17 | P>0.05 | 20.6±4.57 | P>0.05 | 45.6±9.78 | P>0.05 |
分组 | 例数 | 年龄 | 性别 | 病程 | 血糖(mmol/L) | ||
(例) | (岁) | 男 | 女 | (年) | 空腹 | 餐后2小时 | |
试食组 | 51 | 50.9±8.5 | 27 | 24 | 6.5±2.8 | 8.6±1.7 | 13.7±2.5 |
对照组 | 51 | 51.8±9.0 | 26 | 25 | 6.2±2.5 | 8.5±1.6 | 13.4±3.0 |
分组 | 例数 | 磺脲类 | 双胍类 | 磺脲+双胍类 | 未服用 |
试食组 | 51 | 12 | 17 | 2 | 20 |
对照组 | 51 | 13 | 15 | 4 | 19 |
分组 | 空腹血糖 | 餐后2小时血糖 | ||||||
试食前 | 试食后 | 差值 | 下降率 | 试食前 | 试食后 | 差值 | 下降率 | |
试食组 | 8.6±1.7 | 7.1±1.9 | -1.5±1.0** | 17.44±8.16 | 13.7±2.5 | 11.7±2.5 | -2.0±1.4 | 14.60±7.23 |
对照组 | 8.5±1.6 | 8.1±2.0 | -0.4±1.2## | 4.71±10.03## | 13.4±3.0 | 12.7±3.2 | -0.7±2.0## | 5.22±10.70## |
项目 | 例数 | 试食前 | 试食后 | 前后差值 |
血糖(mmol/L) | 51 | 8.6±1.7 | 7.1±1.9 | -1.5±1.0** |
(51) | (8.5±1.6) | (8.1±2.0) | (-0.4±1.2) | |
血胰岛素(μu/L) | 51 | 14.5±6.3 | 13.9±7.6 | |
(51) | ||||
尿糖(积分值) | 51 | 0.9±0.9 | 0.4±1.0 | 0.4±0.9 |
(51) | (0.9±1.0) | (0.7±1.2) | (0.2±1.2) |
分组 | 显效 | 有效 | 无效 | 总有效率(%) | |
试食组 | 例数 | 3 | 27 | 21 | 31 |
功效率(%) | 5.9 | 52.9 | 41.2 | 58.8# | |
对照组 | 例数 | 0 | 11 | 40 | 11 |
功效率(%) | 0.0 | 21.6 | 78.4 | 21.6 |
症状 | 例数 | 显效 | 有效 | 无效 | 改善率(%) |
多食 | 30 | 7 | 13 | 10 | 66.7 |
(31) | (2) | (5) | (24) | (22.6) | |
多饮 | 31 | 3 | 6 | 22 | 29.0 |
(31) | (0) | (5) | (26) | (16.1) | |
多尿 | 25 | 7 | 10 | 8 | 68.0 |
(25) | (1) | (4) | (20) | (20.0) | |
疲倦乏力 | 45 | 18 | 17 | 10 | 77.8 |
(44) | (5) | (10) | (29) | (34.1) |
分组 | 例数 | 试食前 | 试食后 |
试食组 | 51 | 16.2±6.2 | 6.0±5.6** |
对照组 | 51 | 15.8±6.4 | 10.5±6.8** |
试食组(n=51) | 对照组(n=51) | |||
项目 | 试食前 | 试食后 | 试食前 | 试食后 |
TP(g/L) | 72.0±3.6 | 72.6±4.1 | 71.4±3.8 | 71.7±4.1 |
ALB(g/L) | 43.8±7.2 | 45.0±7.4 | 44.3±6.2 | 45.0±7.2 |
ALT(u/L) | 22.5±5.7 | 20.9±5.2 | 21.2±6.3 | 19.5±7.8 |
AST(u/L) | 21.8±7.0 | 23.6±6.2 | 22.4±7.5 | 21.2±8.2 |
UREA(mmol/L) | 5.3±2.4 | 5.5±2.0 | 5.2±2.4 | 5.6±2.1 |
Cr(umol/L) | 92.3±16.1 | 94.6±13.2 | 92.5±15.9 | 93.0±14.8 |
HGB(g/L) | 134.2±16.5 | 136.1±17.1 | 137.9±20.0 | 135.4±20.9 |
RBC(×1012/L) | 4.1±0.7 | 4.3±0.6 | 4.3±0.7 | 4.2±0.7 |
WBC(109/L) | 6.2±1.2 | 6.4±1.4 | 6.1±1.7 | 5.9±1.8 |
尿常规 | 正常 | 正常 | 正常 | 正常 |
便常规 | 正常 | 正常 | 正常 | 正常 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100552651A CN100531783C (zh) | 2007-01-19 | 2007-01-19 | 一种用于辅助降血糖的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100552651A CN100531783C (zh) | 2007-01-19 | 2007-01-19 | 一种用于辅助降血糖的保健食品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101015659A true CN101015659A (zh) | 2007-08-15 |
CN100531783C CN100531783C (zh) | 2009-08-26 |
Family
ID=38724989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100552651A Expired - Fee Related CN100531783C (zh) | 2007-01-19 | 2007-01-19 | 一种用于辅助降血糖的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100531783C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485259A (zh) * | 2010-12-03 | 2012-06-06 | 吉林吉春制药有限公司 | 一种人参果药用分散片、含片的制备方法和应用 |
CN101411469B (zh) * | 2008-12-02 | 2012-06-06 | 富力 | 一种蕨麻提取物食品和生产工艺及其应用 |
CN104351773A (zh) * | 2014-10-27 | 2015-02-18 | 张彩琴 | 一种黄参葛降糖颗粒保健食品的制作方法 |
-
2007
- 2007-01-19 CN CNB2007100552651A patent/CN100531783C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101411469B (zh) * | 2008-12-02 | 2012-06-06 | 富力 | 一种蕨麻提取物食品和生产工艺及其应用 |
CN102485259A (zh) * | 2010-12-03 | 2012-06-06 | 吉林吉春制药有限公司 | 一种人参果药用分散片、含片的制备方法和应用 |
CN104351773A (zh) * | 2014-10-27 | 2015-02-18 | 张彩琴 | 一种黄参葛降糖颗粒保健食品的制作方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100531783C (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101095751B (zh) | 具有祛黄褐斑、改善营养性贫血的药物组合物及制备方法 | |
CN101878906B (zh) | 一种具有辅助降血糖功能的保健食品及其制备方法 | |
CN102551065B (zh) | 一种降糖食品系列 | |
CN104013698A (zh) | 一种具有辅助降血脂功能的纳豆山楂胶囊及其制备方法 | |
CN102090630A (zh) | 增强人体抗氧化的保健品及其制备方法 | |
CN105079089A (zh) | 一种辅助降血糖的葛根苦瓜保健食品制备方法 | |
CN113101342A (zh) | 一种具有辅助降血糖功能的中药组合物及其制备方法 | |
CN101390887A (zh) | 三七总皂苷的药物组合物 | |
CN100531783C (zh) | 一种用于辅助降血糖的保健食品及其制备方法 | |
CN101356975A (zh) | 提高人体免疫及促智健脑的保健食品及其制备方法 | |
CN104001072A (zh) | 一种用于预防和治疗糖尿病的药物组合物 | |
CN103816278A (zh) | 一种用于降低血糖的组合物及其应用 | |
CN104026568B (zh) | 一种保健品组合物 | |
CN107669763B (zh) | 一种浒苔多糖复合辅助降血脂保健品及其制备方法 | |
CN102178718B (zh) | 一种用于治疗糖尿病和防治心脑血管疾病的制剂 | |
CN102068589A (zh) | 降脂减肥的药物组合物及其制备方法 | |
CN101810649A (zh) | 一种松针蒸馏浓缩液的制备方法 | |
CN104173734B (zh) | 一种治疗糖调节受损的药物组合物及其制备方法 | |
CN102578451A (zh) | 一种降血糖的保健食品组合物 | |
CN106421741A (zh) | 水溶性橄榄叶提取物保健品及其制备方法 | |
CN100428951C (zh) | 一种降血糖的保健食品 | |
AU2016313671A1 (en) | Health food and process for preparing the same | |
CN102885300A (zh) | 一种具有降血糖作用的保健食品及其制备方法 | |
CN102488202A (zh) | 用于糖尿病治疗的药用组合物和制备方法 | |
CN101204504A (zh) | 一种防治糖尿病的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN XINKEQI HEALTH-CARE FOOD CO., LTD. Free format text: FORMER OWNER: DONGBEIHU PHARMACEUTICAL CO., LTD. Effective date: 20111231 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111231 Address after: 132013 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee after: Jilin Xinkeqi Health-care Food Co., Ltd. Address before: 132013 No. 2, No. 3, hi tech Zone, Jilin, Jilin Patentee before: Dongbeihu Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 132000 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee after: Jilin cloud Health Food Co., Ltd. Address before: 132013 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee before: Jilin Xinkeqi Health-care Food Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090826 Termination date: 20200119 |
|
CF01 | Termination of patent right due to non-payment of annual fee |